Hogan, J., Perez, A., Sellier-Leclerc, A., Vrillon, I., Broux, F., Nobili, F., Harambat, J., Bessenay, L., Audard, V., Faudeux, C., Morin, D., Pietrement, C., Tellier, S., Djeddi, D., Eckart, P., Lahoche, A., Roussey-Kesler, G., Ulinski, T., Boyer, O., Plaisier, E., Cloarec, S., Jolivot, A., Guigonis, V., Guilmin-Crepon, S., Baudouin, V., Dossier, C., & Deschênes, G. (2020). efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial. BMJ open, 10(9), . http://access.bl.uk/ark:/81055/vdc_100127571548.0x000059